- Home
- VFS vs JAZZ Comparison
VFS vs JAZZ Comparison
Compare VFS & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VFS
- JAZZ
- Stock Information
- Founded
- VFS 2017
- JAZZ 2003
- Country
- VFS Vietnam
- JAZZ Ireland
- Employees
- VFS N/A
- JAZZ N/A
- Industry
- VFS Blank Checks
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- VFS Finance
- JAZZ Health Care
- Exchange
- VFS Nasdaq
- JAZZ Nasdaq
- Market Cap
- VFS 6.8B
- JAZZ 7.3B
- IPO Year
- VFS N/A
- JAZZ 2007
- Fundamental
- Price
- VFS $3.62
- JAZZ $106.59
- Analyst Decision
- VFS Strong Buy
- JAZZ Strong Buy
- Analyst Count
- VFS 4
- JAZZ 13
- Target Price
- VFS $8.17
- JAZZ $181.85
- AVG Volume (30 Days)
- VFS 482.4K
- JAZZ 1.3M
- Earning Date
- VFS 05-23-2025
- JAZZ 05-06-2025
- Dividend Yield
- VFS N/A
- JAZZ N/A
- EPS Growth
- VFS N/A
- JAZZ 49.21
- EPS
- VFS N/A
- JAZZ 7.51
- Revenue
- VFS $1,727,262,130.00
- JAZZ $4,064,808,000.00
- Revenue This Year
- VFS N/A
- JAZZ $6.07
- Revenue Next Year
- VFS $44.69
- JAZZ $4.26
- P/E Ratio
- VFS N/A
- JAZZ $14.37
- Revenue Growth
- VFS 57.87
- JAZZ 5.76
- 52 Week Low
- VFS $2.56
- JAZZ $95.49
- 52 Week High
- VFS $6.42
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- VFS 59.73
- JAZZ 45.66
- Support Level
- VFS $3.40
- JAZZ $97.50
- Resistance Level
- VFS $3.82
- JAZZ $105.28
- Average True Range (ATR)
- VFS 0.14
- JAZZ 4.47
- MACD
- VFS 0.03
- JAZZ -0.10
- Stochastic Oscillator
- VFS 72.22
- JAZZ 39.23
About VFS VinFast Auto Ltd.
VinFast Auto Ltd manufactures cars, and motor vehicles, renders leasing activities, trades smartphones, and related businesses. The company is engaged in designing and manufacturing premium EVs, e-scooters, and e-buses. The company's initial EV product line is an all-new range of fully electric A- through E-segment SUVs. The Company has three reportable segments, namely Automobiles, E-scooter, Spare parts & Aftermarket services. The Automobiles segment includes the design, development, manufacturing, and sales of cars and electric buses; The E-scooter segment includes the design, development, manufacturing, and sales of e-scooters; the Spare parts & Aftermarket services segment includes the sales of spare parts and rendering of aftermarket services for automobiles and e-scooters.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.